Sana Biotechnology to Present Pre-Clinical Data at 2021 American Society of Hematology Annual Meeting

Rhea-AI Summary

Sana Biotechnology (NASDAQ: SANA) announced plans to present data during four poster presentations at the 63rd American Society of Hematology Annual Meeting, taking place from December 11 to December 14, 2021. This event will highlight advancements in Sana's engineered cell therapies, specifically focusing on in vivo CAR T and ex vivo allogeneic CAR T cell programs. CEO Steve Harr expressed excitement over these scientific developments, emphasizing the company’s goal to file its first IND application as early as next year. The abstracts are available online, with full presentations scheduled throughout the event.

Positive

• Presentation of data at ASH indicates ongoing progress in engineered cell therapies.
• Plans to file first IND application as early as next year highlight forward momentum.
• Focus on advanced therapeutic programs may attract investor interest.

Negative

• None.

SEATTLE, Nov. 04, 2021 (GLOBE NEWSWIRE) -- Sana Biotechnology, Inc. (NASDAQ: SANA), a company focused on creating and delivering engineered cells as medicines, today announced that data will be presented during four poster presentations at the 63^rd American Society of Hematology (ASH) Annual Meeting and Exposition, to be held both in person in Atlanta, GA and virtually from Sunday, December 11 to Tuesday, December 14, 2021.

“We are excited to share data at ASH that showcase scientific advancements from our in vivo CAR T and ex vivo allogeneic CAR T cell programs,” said Steve Harr, Sana’s President and CEO. “These presentations and publications mark the growth of our science and our continued progress toward the clinic, as we intend to file our first IND as early as next year. We celebrate our scientists as they work toward our mission of creating and delivering engineered cells as medicines for patients.”

Data on the progress of several of Sana’s programs were outlined in abstracts for poster presentations, which were made available to the public online today. Information about when the full posters will be available to ASH conference participants is outlined below.

Engineered hypoimmune allogeneic CAR T cells exhibit innate and adaptive immune evasion even after sensitization in humanized mice and retain potent anti-tumor activity

• Abstract 1690 (Poster Presentation)
• Session Name: 703. Cellular Immunotherapies: Basic and Translational: Poster I 
  • The session opens for viewing on Saturday, December 11, 2021, at 9:00 a.m. ET. Presentations are on Saturday, December 11, 2021, from 5:30 to 7:30 p.m. ET for in-person participants in the Georgia World Congress Center, Hall B5.
  • Presenter: Sonja Schrepfer
• In addition, this abstract will be published online in the November supplemental issue of Blood, the journal of the American Society of Hematology.
  

In vivo delivery of a CD20 CAR using a CD8-targeted fusosome in Southern pig-tail macaques (M. nemestrina) results in B cell depletion

• Abstract 2769 (Poster Presentation)
• Session Name: 703. Cellular Immunotherapies: Basic and Translational: Poster II
  • The session opens for viewing on Sunday, December 12, 2021, at 9:00 a.m. ET. Presentations are on Sunday, December 12, 2021, from 6:00 to 8:00 p.m. ET for in-person participants in the Georgia World Congress Center, Hall B5.
  • Presenter: Terry Fry
• In addition, this abstract will be published online in the November supplemental issue of Blood, the journal of the American Society of Hematology.
  

CD4-targeted fusosomes are capable of transducing resting T helper cells to generate highly potent CAR T cells

• Abstract 2942 (Poster Presentation)
• Session Name: 703. Cellular Immunotherapies: Basic and Translational: Poster II
  • The session opens for viewing on Sunday, December 12, 2021, at 9:00 a.m. ET. Presentations are on Sunday, December 12, 2021, from 6:00 to 8:00 p.m. ET for in-person participants in the Georgia World Congress Center, Hall B5.
  • Presenter: Christie Ciarlo
• In addition, this abstract will be published online in the November supplemental issue of Blood, the journal of the American Society of Hematology.
  

Specificity of CD8-targeted fusosomes in human PBMCs using single cell RNA and T cell receptor sequencing

• Abstract 3983 (Poster Presentation)
• Session Name: 801. Gene Therapies: Poster III.
  • The session opens for viewing on Monday, December 13, 2021, at 9:00 a.m. ET. Presentations are on Monday, December 13, 2021, from 6:00 to 8:00 p.m. ET for in-person participants in the Georgia World Congress Center, Hall B5.
  • Presenter: Hina Iftikhar
• In addition, this abstract will be published online in the November supplemental issue of Blood, the journal of the American Society of Hematology.
  

Abstracts are available online on the ASH meeting website as of November 4, 2021, at 9:00 a.m. ET. Learn more at https://www.hematology.org/meetings/annual-meeting.

About Sana Biotechnology
Sana Biotechnology, Inc. is focused on creating and delivering engineered cells as medicines for patients. We share a vision of repairing and controlling genes, replacing missing or damaged cells, and making our therapies broadly available to patients. We are more than 320 people working together to create an enduring company that changes how the world treats disease. Sana has operations in Seattle, Cambridge, and South San Francisco. For more information about Sana Biotechnology, please visit https://sana.com/.

Cautionary Note Regarding Forward-Looking Statements
This press release contains forward-looking statements about Sana Biotechnology, Inc. (the “Company,” “we,” “us,” or “our”) within the meaning of the federal securities laws, including those related to the Company’s vision, progress, and business plans; expectations for its development programs, product candidates and technology platforms, including its pre-clinical, clinical and regulatory development plans and timing expectations; the potential uses and advantages of hypoimmune CAR T cells and fusosome technology, including CD4-specific fusosomes and CD8a-targeted fusosomes; expectations for the publication of data, including in medical or scientific journals; and expectations for and the content of the Company’s presentations at the 63^rd American Society of Hematology Annual Meeting and Exposition. All statements other than statements of historical facts contained in this press release, including, among others, statements regarding the Company’s strategy, expectations, cash runway and future financial condition, future operations, and prospects, are forward-looking statements. In some cases, you can identify forward-looking statements by terminology such as “aim,” “anticipate,” “assume,” “believe,” “contemplate,” “continue,” “could,” “design,” “due,” “estimate,” “expect,” “goal,” “intend,” “may,” “objective,” “plan,” “positioned,” “potential,” “predict,” “seek,” “should,” “target,” “will,” “would” and other similar expressions that are predictions of or indicate future events and future trends, or the negative of these terms or other comparable terminology. The Company has based these forward-looking statements largely on its current expectations, estimates, forecasts and projections about future events and financial trends that it believes may affect its financial condition, results of operations, business strategy and financial needs. In light of the significant uncertainties in these forward-looking statements, you should not rely upon forward-looking statements as predictions of future events. These statements are subject to risks and uncertainties that could cause the actual results to vary materially, including, among others, the risks inherent in drug development such as those associated with the initiation, cost, timing, progress and results of the Company’s current and future research and development programs, preclinical and clinical trials, as well as the economic, market and social disruptions due to the ongoing COVID-19 public health crisis. For a detailed discussion of the risk factors that could affect the Company’s actual results, please refer to the risk factors identified in the Company’s SEC reports, including but not limited to its Annual Report on Form 10-K dated March 24, 2021 and Quarterly Report on Form 10-Q dated August 4, 2021. Except as required by law, the Company undertakes no obligation to update publicly any forward-looking statements for any reason.

All product and company names herein may be trademarks of their registered owners.

Investor Relations:
Nicole Keith
investor.relations@sana.com

Media:
Morgan Warners, Finsbury Glover Hering
media@sana.com

FAQ

What data will Sana Biotechnology present at the ASH Annual Meeting?

Sana will present data on their in vivo CAR T and ex vivo allogeneic CAR T cell programs during four poster presentations.

What is the significance of Sana Biotechnology filing its first IND?

Filing its first IND is a crucial step in the regulatory process that allows the company to begin clinical trials, marking progress in their development pipeline.

When is the ASH Annual Meeting taking place?

The ASH Annual Meeting will be held from December 11 to December 14, 2021, both in-person in Atlanta, GA and virtually.

Where can I find the abstracts for Sana Biotechnology's presentations?

The abstracts for Sana's presentations are available online on the ASH meeting website as of November 4, 2021.

Who is presenting Sana's research at the ASH meeting?

Various presenters, including Sonja Schrepfer and Terry Fry, will present Sana's research during the meeting.